Asker Healthcare Group AB: Issuance, repurchase and reclassification of Class C shares under incentive program in Asker Healthcare Group
Today, on 9 March 2026, the Board of Directors of Asker Healthcare Group AB (publ) ("Asker") has resolved to issue 670,000 new Class C shares and to immediately thereafter repurchase and reclassify all of the issued Class C shares into ordinary shares.
The purpose of the issuance, repurchase and reclassification is to ensure the delivery of ordinary shares to employees within the Asker group in accordance with Asker's long-term performance-based investment share program, which was adopted by the Extraordinary General Meeting on 27 August 2025 ("LTIP 2025").
By virtue of the authorization granted by the Extraordinary General Meeting on 27 August 2025, the Board of Directors has resolved to increase the share capital by SEK 982.245338 through a directed cash issue of 670,000 Class C shares to Nordea Bank Abp, filial i Sverige ("Nordea"), at a subscription price corresponding to the quota value of the shares. Furthermore, the Board of Directors has resolved to immediately repurchase all of the issued Class C shares from Nordea at the same price as the subscription price and to reclassify all of the issued Class C shares into ordinary shares.
Following the completion of the issuance, repurchase and reclassification, the total number of shares in Asker will amount to 383,706,497 ordinary shares. The 670,000 reclassified ordinary shares will be held by Asker for delivery to participants under LTIP 2025. As of the date of this press release, Asker does not hold any treasury shares.
For further information, please contact:
Emma Rheborg, Head of Communication Asker Healthcare Group
Phone: +46 73 313 62 17
E-mail: emma.rheborg@asker.com
The information was submitted for publication, through the agency of the contact person set out above, at 13:30 CET on 9 March 2026.
Asker Healthcare Group is a partner to caregivers and patients across Europe providing medical products and solutions. We build and acquire leading companies that together support the healthcare system to improve patient outcomes, reduce total cost of care and ensure a fair and sustainable value chain. We are a European healthcare group that combines the entrepreneurial drive of strong local companies, with the abilities and collected knowledge of a large group - driving progress in the healthcare sector. The group has more than 4 500 employees in 19 countries and revenues amounting to SEK 17 billion.